Prostate Cancer Clinical Trial
Official title:
Active Surveillance Plus (AS+): Local Tumor Control With High-intensity Focused Ultrasound (HIFU) in Patients With Localized Prostate Cancer
PSA (Prostate-specific antigen) testing has significantly increased the number of men diagnosed with prostate cancer (PCa) and especially patients with low and intermediate risk disease. The effect of radical treatment (treatment of the entire prostate gland) in these risk groups is disputable while the risk of adverse effects, with erectile dysfunction and urinary incontinence, is not. Active surveillance (AS) has been developed as an alternative to radical treatment with the aim of avoiding or delaying radical treatment by closely monitoring for signs of tumor progression. Active surveillance is regarded as the treatment of choice for low-risk prostate cancer. Focal therapy may have a crucial role in improving active surveillance protocols for patients with intermediate localized prostate cancer. Focal eradication of the index-tumor may delay or avoid indefinitely radical treatment for this patient group while significantly reducing treatment-related side effects. Improved MRI-diagnostics and MRI/ ultrasound fusion technology have optimized tumor mapping and classification and this in turn has made partial treatment of the prostate a feasible treatment option. This study is a prospective cohort study. Patients with intermediate (high-risk) localized PCa and a visible index tumor will be treated with high-intensity focused ultrasound (HIFU). The aim of the study is to show that there is a significant effect of focal treatment on surveillance biopsies and a reduced conversion to radical treatment, without compromising survival outcomes compared to historical controls (retrospective cohort). A cohort from the more than 450 patients included in the local AS-protocol with MRI at Vestfold hospital trust since 2009 will serve as controls.
Status | Recruiting |
Enrollment | 250 |
Est. completion date | September 2030 |
Est. primary completion date | September 2030 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Age 55-80 years - Life expectancy >10 years - Gleason-score: - patients <75 years: Gleason score < 8 - patients 75-80 years: Gleason <9 - TNM-stage: clinical/ radiological stage <T2c (localized), rN0 and rM0 - PSA < 15 - PSA > 15 should be counseled with caution (does not apply to patients >75 years) - Risk group: d'Amico intermediary risk group, open for high risk patients age >75 years Exclusion Criteria: - Previous treatment - Previous treatment of the primary cancer within the prostate - Previous hormone treatment for prostate cancer within 6 months before trial - Previous radiation to pelvis - Acute urinary tract infection - For patients <75 years: >5% chance of lymph node metastases calculated by the updated prostate cancer staging nomogram (Partin tables) (30) - Radiological imaging: - PI-RADS score <3, clinical significant cancer is equivocal - Extracapsular extension or seminal vesicle invasion - Lymph node or bone metastasis - > 2 MRI detected tumors validated by systematic or MRI-guided biopsies - Contraindications for MRI |
Country | Name | City | State |
---|---|---|---|
Norway | Vestfold Hospital Trust (Hospital of Vestfold) | Tønsberg | Vestfold |
Lead Sponsor | Collaborator |
---|---|
The Hospital of Vestfold |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients without clinically significant prostate cancer | Absence of clinically significant prostate cancer (Gleason grade =7A) on post-treatment systematic and targeted biopsies | 1-10 years | |
Primary | Measurement of functional results | erectile function, continence, and other therapy-related complications. Questionnaire-based. | 1-10 years | |
Primary | Number of patients who need repeated focal treatment | recurrence and recurrent treatment | 1-10 years | |
Primary | Number of patients eligible for continuous AS+ | 1-10 years | ||
Primary | Disease-free survival | based on repeated MRI and repeat biopsies performed on clinical/ radiological suspicion | 1-10 years | |
Primary | Treatment-free survival | 1-10 years | ||
Primary | Overall survival | 1-10 years | ||
Primary | Metastasis-free survival | 1-10 years | ||
Primary | Number of patients who need radical (surgery or radiation), or palliative treatment (hormone therapy) | 1-10 years | ||
Secondary | Number of patients where MRI predicted tumor recurrence/ tumor absence | MRI findings verified by biopsies | 1-10 years | |
Secondary | Patient Reported Outcomes Measures | Survey-based using standard questionaires | 1-10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |